This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations
BMC Genomic Data Open Access 07 August 2023
-
Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders
Scientific Reports Open Access 28 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Dong M, Blobe GC . Role of transforming growth factor-β in hematological malignancies. Blood 2006; 107: 4586–4596.
Coffman JA . Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 2003; 27: 315–324.
Otto F, Stock M, Fliegauf M, Fenaux P, Preudhomme C, Lübbert M . Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia. Leukemia 2003; 17: 1677–1678.
Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19: 402–409.
Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113–124.
Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC et al. RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 2006; 25: 7646–7649.
Acknowledgements
HPK is a member of the Johnsson Cancer Center, the Molecular Biology Institute of UCLA and has the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. This work was also supported, in part, by a fellowship from the Deutsche Forschungsgemeinschaft to CIM (MU 1809/1), and by an International Visiting Fellowship from Leukaemia Research Fund (UK) to QTL (no. 0340).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Müller, C., Luong, Q., Shih, LY. et al. Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals. Leukemia 22, 1773–1778 (2008). https://doi.org/10.1038/leu.2008.41
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.41
This article is cited by
-
Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations
BMC Genomic Data (2023)
-
Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders
Scientific Reports (2016)